Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial

2019236 citationsJournal Article

Authors

Good health and well-being

Published in: The Lancet Haematology

Volume 6, Issue 1, pp. e12-e19

Field-Weighted Citation Impact: 23.41